Phentermine Hydrochloride

REDWOOD CITY, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, presented “Oral long-acting menin inhibitor normalizes type 2 diabetes in two rat models” at the European Association for the Study of Diabetes Annual Meeting (EASD). The presentation highlighted BMF-219’s ability to improve pancreatic beta cell area and function in two preclinical rat models of diabetes. This data showed BMF-219’s robust and prolonged glycemic control, insulin sensitization, and reduction of weight and lipid levels in preclinical rat models. In addition, and for the first time, Biomea Fusion presented data showing an increase in beta cell function based on HOMA-B determination in the two rat models and an increase in beta-cell area in the ZDF rat model and an increase in beta cell mass in an ex-vivo human donor beta-cell islet model. This data provides further support for the potential of BMF-219 as a long-acting, disease modifying treatment for type 2 diabetes. The preclinical presentations from EASD can be viewed on Biomea’s website at https://biomeafusion.com/publications. “Today we reported direct evidence of BMF-219’s ability to increase beta cell area, another key feature of the novel mechanism. BMF-219 also displayed the ability to restore and preserve beta cell function in various type 2 diabetes models. In addition, we have continued to expand our translational work and presented a preview of the results today, showing treatment with BMF-219 led to a substantial expansion of human beta cells in an ex-vivo donor islet model,” said Thomas Butler, CEO and Chairman of Biomea Fusion. Diabetes is a multi-factorial disease that typically requires daily treatment with multiple agents with various mechanisms of action to achieve glycemic control. The global burden of diabetes has been rapidly increasing with over 400 million people currently struggling with diabetes globally. “These results, along with additional work, increases our understanding and our confidence in BMF-219’s ability to restore and balance beta cell mass effectively and efficiently. We are excited about the potential impact a treatment like this can have on the lives of the millions of patients worldwide with diabetes. Today, available therapies only provide symptomatic control whereas BMF-219 has the potential to be disease modifying. We look forward to updating you on our clinical development plan in diabetes in the coming months,” commented Mr. Butler The data presented at EASD shows that BMF-219 was superior to pioglitazone in an oral glucose tolerance test (OGTT), an assessment of glucose metabolism and processing, in the STZ beta cell ablation model during the treatment period. In this model, BMF-219 but not active comparator, pioglitazone, restored non-fasting glucose levels to near normal baseline by treatment day eight and significantly reduced blood glucose levels vs. vehicle and pioglitazone during the OGTT in STZ rats (mean AUC reduction of 41%, p<0.05) at day 15, suggesting that BMF-219 rapidly induced pancreatic beta cell regrowth and function. Furthermore, BMF-219 administration resulted in a near doubling of HOOMA-B value compared to vehicle control and pioglitazone in the STZ rat model. In the other gold standard type 2 diabetes model, ZDF rats treated with BMF-219 exhibited an increase in beta cell mass and function while on BMF-219 and for two weeks after BMF-219 was removed. ZDF rats treated with vehicle and pioglitazone saw a reduction in IHC-Insulin staining, a proxy for beta cell mass of -33% and -28%, respectively, while rats treated with BMF-219 saw an increase of +2%. Two weeks after BMF-219 treatment, the ZDF rats continued to see a normalization of their HOMA-B score, with approximately 350% improvement compared to vehicle treated ZDF rats, which remained highly diabetic with poor beta cell function (~75% below the normal range). In the ZDF model, BMF-219 and pioglitazone showed similar glycemic control during an OGTT while drug was present (AUC reduction of 54%, p<0.001) but only BMF-219 treated rats saw weight loss during treatment with BMF-219 and maintained glycemic control two weeks after washout (AUC reduction of 40%, p<0.05), indicating prolonged glycemic control. In addition to OGTT, blood glucose, insulin, C-peptide, Hemoglobin A1C (HbA1c), lipemic levels, and weight were also assessed. We believe these data collectively demonstrate the novel, long-acting potential of BMF-219 as a single agent, disease modifying oral treatment for type 2 diabetes. About Menin in Diabetes Loss of functional beta-cell mass is a core component of the natural history in both types of diabetes — type 1 diabetes (mediated by autoimmune dysfunction) and type 2 diabetes (mediated by metabolic dysfunction). Beta-cells are found in the pancreas and are responsible for the synthesis and secretion of insulin. Insulin is a hormone that helps the body use glucose for energy and helps control blood glucose levels. In patients with diabetes, beta-cell mass and function are diminished, leading to insufficient insulin secretion and hyperglycemia. Menin is thought to act as a brake on beta-cell turnover / beta-cell growth, supporting the notion that inhibition of menin could lead to the regeneration of normal healthy beta-cells. Based on these and other scientific findings, Biomea explored the potential for menin inhibition as a viable therapeutic approach to permanently halt or reverse progression of type 2 diabetes. About Biomea Fusion Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION™ System to advance a pipeline of covalent-binding therapeutic agents against key oncogenic drivers of cancer and metabolic diseases. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing covalent small molecules in order to maximize the clinical benefit when treating various cancers and metabolic diseases.

Basel, Switzerland, 29 August 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases today announced that the first patient has been dosed in the Phase 2 KINFAST trial, a multicenter placebo-controlled trial evaluating KIN001 in mild or moderate COVID-19 patients in an outpatient setting. The trial will enroll patients at clinical trial sites in Switzerland and Germany. The KINFAST trial is partly supported by a non-diluting grant from the Programme for COVID-19 medicines of the Swiss Federal Office of Public Health. KIN001 is an orally administered combination of two drugs that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis. In contrast to other antivirals and monoclonal antibody therapies, which target SARS-Cov2 directly, KIN001 targets human host cell pathways required for SARS-Cov2 viral replication, blocking the virus’ ability to replicate and reducing potential for the emergence of escape mutants. Kinarus and its collaborators recently published data in the peer-reviewed International Journal of Molecular Sciences demonstrating KIN001’s strong antiviral efficacy and equal potency against the original SARS-CoV-2 strain and variants of concern (VOC), including delta and omicron. “This important milestone demonstrates the potential of KIN001 to address all severities of COVID-19 with potential for wide use in early and later stages of the disease,” said Thierry Fumeaux M.D., MBA, Chief Medical Officer of Kinarus Therapeutics, and former Head of the Clinical Expert Group on the COVID-19 Task Force mandated by the Swiss Federal Council. “With the initiation of this global Phase 2 program, we are one step closer to achieving our goal of providing an easily administered oral drug with multiple synergistic mechanisms that fight and treat SARS-Cov2 infection, independent of the variant. KIN001 aims to prevent disease progression thereby reducing disease severity as well as hospitalizations.” Kinarus previously provided an update on progress of its first Phase 2 clinical trial of KIN001 to treat hospitalized COVID-19 patients (“KINETIC”). KINETIC had enrolled 131 patients as of June 6, 2022, and interim data are expected to be available late in Q3 2022. Last week, Kinarus held and published on its website a webinar on KIN001’s potential to treat COVID-19 infection (https://ir.kinarus.com/reports-presentations/#presentations). KINFAST is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, outpatient study to evaluate the efficacy, safety, and pharmacokinetic profile of KIN001 in patients with mild or moderate COVID-19. The study is expected to enroll approximately 400 non-hospitalized patients with confirmed mild to moderate symptoms and confirmed SARS-CoV-2 infection with an interim assessment after enrolling about 140 patients. Patients will be randomized within 5 days of symptom onset. The primary endpoint is the time to recovery, based on the daily symptoms’ evaluation by the patient (patient-reported outcome developed by the FDA). Other efficacy endpoints will include number of patients requiring hospitalization for COVID-19, as well as the total burden of symptoms (severity and duration), as assessed by the patient. KIN001 is a patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes. Several p38 MAPK inhibitors were studied by the pharmaceutical industry and largely abandoned after promising but only transient efficacy was observed. Kinarus discovered through its own research that the combination of pamapimod with pioglitazone (i.e., KIN001) produced synergistic efficacy and increased the durability of pamapimod’s effects in preclinical models representing several disease indications. KIN001 enjoys broad patent protection in the US, EU, China, and other countries through at least 2037. Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus team utilizes its knowledge and drug development competencies to in-license and develop mid-stage clinical assets in which they have identified an increased probability of clinical and regulatory success and a rapid path to market. Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.